Freedom of Information Request: 0794 2020/21
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
I have a Freedom of Information request regarding Ophthalmology. Could you kindly provide the answers to the questions mentioned below?
Queen Elizabeth Hospital Birmingham:
- Within your trust how many intra-vitreal injections/implants of each of the following drugs have been used in the four-month period from January to April 2020:
| Drug | Number of patients |
| Abicipar pegol | 0 |
| Aflibercept | 0 |
| Bevacizumab | 0 |
| Brolucizumab | 0 |
| Dexamethasone | 2435 |
| Fluocinolone | 0 |
| Ranibizumab | 0 |
- If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:
Wet Age Related Macular Degeneration (wAMD)
| Drug | Number of patients |
| Abicipar pegol | 0 |
| Aflibercept | 0 |
| Bevacizumab | 0 |
| Brolucizumab | 0 |
| Dexamethasone | 6 |
| Fluocinolone | 0 |
| Ranibizumab | 0 |
Diabetic Macular Oedema (DMO)
| Drug | Number of patients |
| Abicipar pegol | 0 |
| Aflibercept | 0 |
| Bevacizumab | 0 |
| Brolucizumab | 0 |
| Dexamethasone | 247 |
| Fluocinolone | 0 |
| Ranibizumab | 0 |
Retinal Vein Occlusion – Central (CRVO)
Retinal Vein Occlusion – Branch (BRVO)
Please note the below information is for both Central and Branch Retinal Vein Occlusion, as the medical code used to query the data is the same.
| Drug | Number of patients |
| Abicipar pegol | 0 |
| Aflibercept | 0 |
| Bevacizumab | 0 |
| Brolucizumab | 0 |
| Dexamethasone | 247 |
| Fluocinolone | 0 |
| Ranibizumab | 0 |
Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)
| Drug | Number of patients |
| Abicipar pegol | 0 |
| Aflibercept | 0 |
| Bevacizumab | 0 |
| Brolucizumab | 0 |
| Dexamethasone | 2 |
| Fluocinolone | 0 |
| Ranibizumab | 0 |
Heartlands, Good Hope and Solihull Hospitals
- Within your trust how many intra-vitreal injections/implants of each of the following drugs have been used in the four-month period from January to April 2020:Please note we can only provide the units issued
| Drug | Units Issued |
| Abicipar pegol | 0 |
| Aflibercept | 1456 |
| Bevacizumab | 39 |
| Brolucizumab | 0 |
| Dexamethasone | 59 |
| Fluocinolone | 1 |
| Ranibizumab | 1414 |
- If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:
We do not hold the information for the below queries centrally, we are unable to provide this data by condition
Wet Age Related Macular Degeneration (wAMD)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Diabetic Macular Oedema (DMO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion – Central (CRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion – Branch (BRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
